Insomnia Disorder clinical trials

Explore recruiting insomnia disorder clinical trials.

Recruiting insomnia disorder studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Insomnia Disorder trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Efficacy and tolerability of tasipimidine after 3 repeated bed-time doses in patients with insomnia disorder with a 4-week extension part

Finland, Poland, Germany

Therapeutic exploratory (Phase II) EU CTIS Study details

Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dosefinding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder

Germany, Bulgaria, Spain, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A MULTICENTER, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFECTS OF TASIMELTEON VS. PLACEBO IN TREATING PEDIATRIC INSOMNIA

Poland, Germany

Therapeutic confirmatory (Phase III) EU CTIS Study details

DARIdorexant efficacy on the COGnitive performance in patients with chronic insomnia disorder. DARI-COG Study

Italy

Therapeutic use (Phase IV) EU CTIS Study details

Daridorexant to treat insomnia in patients with mild cognitive impairment and mild to moderate Alzheimer disease.

France

Therapeutic use (Phase IV) EU CTIS Study details

A multi-center, double-blind, randomized, placebo-controlled, 2-way cross-over post approval study to investigate the efficacy of daridorexant in subjects with insomnia and comorbid nocturia

Spain, Germany

Therapeutic use (Phase IV) EU CTIS Study details

Insomnia Disorder trials by city

Insomnia Disorder in Toronto Insomnia Disorder in Vancouver Insomnia Disorder in Montreal Insomnia Disorder in Calgary Insomnia Disorder in Edmonton Insomnia Disorder in Ottawa Insomnia Disorder in Winnipeg Insomnia Disorder in Quebec City Insomnia Disorder in Hamilton Insomnia Disorder in Kitchener Insomnia Disorder in London Insomnia Disorder in Halifax Insomnia Disorder in New York Insomnia Disorder in Los Angeles Insomnia Disorder in Chicago Insomnia Disorder in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease